focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
What on earth are you talking about??? CMS is NOT an AIM stock! Current valuation is low due to their failure to meet forecasted targets over the previous 2 years and also the recent profit warning from St Ives. Providing they achieve their current year forecasts the price should climb back up into the mid 50's.
"Compelling growth potential" http://www.aimzine.co.uk/ http://www.thesundaytimes.co.uk/sto/business/energy_and_environment/article985621.ece
Highlights · 6% increase in pre-tax profits to £5.0m · Revenue in principal trading divisions up 9% to £16.5m · Earnings per share up 10% to 3.79p · Steady and profitable underwriting results with a claims ratio of 65.2% · Shareholders' funds up to £26.9m · 12% increase in half year dividend to 1.9p (H1 2010: 1.7p) · Outlook encouraging, ongoing demand for services and continued opportunities for both legal & specialist tax services http://www.investegate.co.uk/Article.aspx?id=201109010700083642N
Share price has been drifting down for 2 months now witth several institutions reducing their positions. Anyone have any insight why ?
I bought Entertainment Rights (ETO) 5,000 shares at 83.9. I've been meaning to buy these for a few weeks and I was waiting for a sign of an upward move. I waiting a bit to long silly me and bought after it had already gone up a bit. However I think this one could have a very nice run next year and I've bought these on a long-term view to double my money over 1-2 years. It's in the film and kids tv market - I should know how well it's doing as two of its biggest shows - Peppa Pig and Ben and Holly's Little Kingdom are two of Christopher's favourites. Peppa Pig is just hitting the US but Ben and Holly - a terrific show - is just getting going and looks set to become a classic. This company has a real eye for a hit and despite the debt being a little higher than I'd normally allow this one looks a cracker of the future - the recent move from the AIM to main market shows management are serious about the growth. So, I expect to tuck these away for some lovely gains. Target 120 stop 69. http://www.nakedtrader.co.uk/index.htm
Peel Hunt view: The company has performed strongly over the first half with a positive outlook. At this stage we are not moving our forecasts up, but are highly confident that our expectations will be met. We are encouraged by the growth coming from all parts of the business and the expansion of the group’s distribution network, which now includes South Africa and Scandinavia. We expect the company to report headline EPS of 13.5p (12.8p adjusted for share option costs, up 22% on FY2010), putting the shares on a FY2011E PER of 5.6x. This looks good value for a genuine international growth stock and we reiterate our Buy stance. Target Price 115p
Should be listed on the main market within 4 weeks !
Up 13% to 314p over the past 2 weeks and moving from AIM to the main market next month ! This could see 350p before Christmas !
This stock has been tipped by Investors Chronicle, Small Company Share Watch and Red Hot Penny Shares over the last 4 weeks so it is likely to attract a very strong following over the next few months.
Abbey Protection plc ("Abbey Protection" or the "Group"), the specialist supplier of legal and professional fees insurance products and services to UK small-to-medium sized enterprises, today announces interim results for the six months ended 30 June 2010. Highlights � 11% increase in pre-tax profits to GBP4.7m � Revenue in core trading divisions, Abbey Legal Protection and Abbey Tax Protection, up 11% (to GBP8.2m) � Earnings per share up 11% to 3.44p � Steady and profitable underwriting results with a claims ratio of 63.3% � Shareholders' funds up to GBP23.8m � Half year dividend of 1.7p (H1 2009: 1.6p) � Outlook positive, with a continued robust demand for services Colin Davison, Chief Executive Officer, commented: "I'm delighted to report another solid set of results for Abbey Protection, which once again underline our ability and resilience to grow the business against a tough economic backdrop and the continued low interest rate environment. Our non-cyclical business model has enabled us to produce sustained organic growth in group revenues and profits during the period. We continue to investigate the acquisition of complementary businesses and are well placed to take advantage of the opportunities likely to be afforded by the deregulation of the legal services sector in 2011." I am pleased to report that our results have held up well against a difficult economic backdrop and the continued low interest rate environment, with an 11% increase in profit before tax to GBP4.7m (2009:GBP4.3m). The resilience of our core business model is demonstrated, in particular, by the underlying performance of our principal trading divisions (Abbey Legal and Abbey Tax) where revenues increased by 11% to GBP8.2m (2009:GBP7.4m) and profits were up 18% to GBP2.3m (2009:GBP1.9m). We remain confident about the Group's prospects for the remainder of the year and beyond, as we have demonstrated our resilience and ability to grow the business in tough economic times. We are committed to maintaining the highest standards of service and this philosophy will enable us to not only maintain, but also enhance our position as the market leader in the supply of legal and professional fees insurance to UK SMEs and maintain the strong organic growth in revenue and profits.
This is an impressive niche b2b insurance company that has increased revenues and profits year 0n year since listing on AIM. Also pays a dividend with a current yield of 5%. http://www.advfn.com/p.php?pid=nmona&article=44215564
This seems to have bottomed out and recent share buy backs and director purchases suggest that this is oversold and due a reversal.
Hoodless Brennan: Cryosave (CRYO, 465p, £44.8m) Europe’s leading stem cell bank commented on proposed new legislation in France supporting the collection and preservation of umbilical cord blood stem cells for future therapeutic use. The group cites that in Europe parents are already offered options to privately store umbilical cord and cord blood stem cells. This proposed legislation should help promote awareness of cord blood banking. With 850k births this year France has the potential to become the largest cord blood market in Europe. This is good news for the company which has had a strong run since we advocated buying the shares at 267.5p (53.5p prior to 5:1 share consolidation) back in April and Cryosave has also bought in its own shares in that time. The valuation has been corrected and the company has surpassed our earlier price target which, adjusted, would amount to 350p per share. On a near term view it is expensive at 17x 2009 while the rating becomes more reasonable at 12x 2010 earnings. Although it has exceeded our original price target the news flow and passing of time enables us to raise the target price to 594p – which would be 15x 2010. Still a BUY.
UK ANALYST: From its inception in 2000, Cryo-Save has become the leading umbilical cord blood storage company in Europe. Its current count of around 100,000 samples stored in its facilities represents a 50% market share - twice that of Vita34, the region's second largest player. Cryo-Save has moved quickly to capture market share, which puts it in an excellent position for future growth. As cord blood storage becomes more commonplace, it is likely that it will be the larger players who benefit the most, as parents will seek the trust and security that only an established leading player can offer. Moreover, there is also the potential for Cryo-Save to benefit from any decisions by national health services to undertake cord blood storage, as tight budgets should ensure that outsourcing is preferable over any in-house expenditure. There are substantial opportunities for growth both in Cryo-Save's core European market and internationally. In Europe the firm is well placed to take advantage of legislative changes in individual countries is currently prohibited. For example, France, which recently proposed new legislation supporting the collection and preservation of umbilical cord blood stem cells, has the potential to become the largest cord blood market in Europe with 850,000 births per year. At an emerging market level, stem cell storage is in an even more infantile stage than it is in Europe and the market potential is much greater. The Group expects to enter these markets using local partners and consequently without incurring significant start up cost. All told, Cryo-Save now operates in 38 countries. Cryo-Save's most recent (interim) results showed underlying (pre-exceptional) pre-tax profit up by 17% to 2.1 million euros on revenues up by 52% to 18.6 million euros. Cash of 2.6 million euros was generated from operating activities, and net cash stood at 4.5 million euros at the period end (30 June). Strong organic growth in Spain, Italy and South Eastern Europe helped the firm store 7,000 samples during the second quarter, marking an all-time record for the firm. More recently, it went on to top this record during the third quarter, when it stored 7,300 samples - up 12% on Q3 2008 and up 4% on Q2 2009. Cryo-Save stored 20,600 samples during the first three quarters of 2009, including 7,300 samples in Q3. Given recent patterns, it should easily meet broker Daniel Stewart's forecast of 27,165 samples stored for the full year. Moreover, with expansion continuing apace, and with price increases filtering through, the firm should continue to experience double-digit growth into the foreseeable future. For the current year to 31 December the broker anticipates pre-tax profits of 4.2 million euros on turnover of 37.3 million euros, which would result in earnings per share of 29.9p. Looking to 2010, the respective figures are 6m euros, 43.5m euros and 43.5p. On that basis, the shares trade on a forward rating of just 10.3. Buy at 450p.
DS have issued a Buy note with a price target of £7.68. Also recommended by UK Analyst: http://**************/shop/page-article/action-article.show/id-130002395
The Serious Fraud Office has been asked to investigate the collapse of Aero Inventory, the airline parts supplier. ....Shareholders, including Gartmore and HSBC, are unlikely to receive anything, said KPMG, the administrator. http://business.timesonline.co.uk/tol/business/industry_sectors/consumer_goods/article6945956.ece
Interesting post from TMF. Directors taking substantial salaries and bonuses in this company. http://www.fool.co.uk/news/investing/company-comment/2009/09/09/alices-agms-cybit-holdings.aspx
Mail Online 11th September 2009 MARKET REPORT: Footsie warms to merger talk Mediterranean Oil & Gas shares firmed 21/2p to 551/2p on talk a bid was coming its way. http://www.dailymail.co.uk/money/article-1212862/MARKET-REPORT-Footsie-warms-merger-talk.html
GoIndustry-DoveBid plc, the AIM quoted global provider of asset management, auction and valuations services, notes the recent movement in its share price and confirms that it knows no reason for the price rise.The Company confirms that it is currently exploring a number of options including a placing of new equity at a significant discount to the current market price (being the closing price on 13 August 2009). In addition, the Company is holding discussions with the holders of the 2011 convertible loan note regarding possible amendments to the agreement, including the possibility of allowing conversion of all or some of the loan notes into ordinary shares at a conversion rate which is at a significant discount to the current market price (being the closing price on 13 August 2009). A further announcement will be made in due course. http://www.londonstockexchange.com/exchange/prices-and-news/news/market-news/market-news-detail.html?announcementId=10151734
Recent fall seems to have levelled off at 21.5p. Good value at this price !